JPRN-UMIN000014443尚未招募2 期
Effectiveness and feasibility of afatinibe in EGFR mutated non-small cell lung cancer patients with postoperative recurrence. -Phase II study- - Effectiveness and feasibility of afatinibe in postoperative recurrent EGFR mutated lung cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients were excluded 1)if they had interstitial pneumonia, pneumoconiosis, Radiation pneumonitis, drug-induced pneumonia. 2)Patient had already received EGFR-TKI 3)Patient had uncontrollable pleural effusion, ascites, pericardial effusion 4)Patient had uncontrolled concomitant diseases, baseline organ function. 5)Patients suspected of being pregnant or lactating women 6)Patients had brain tumors and/or brain metastases (symptomatic or requiring treatment) 7)Patients had additional significant malignancies diagnosed within the past 5 years 8)Tumour tissue had to T790M EGFR mutation
研究者
相似试验
进行中（未招募）
不适用
Afatinib translational study in patients with EGFR mutation-positive non-squamous non-small cell lung cancer acquired resistance to osimertinibEGFR mutation-positive non-squamous non-small cell lung cancerJPRN-jRCTs071180013Ryo Toyozawa30
招募中
Unknown
Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinibon-small cell lung cancerJPRN-UMIN000049225Shinshu University School of Medicine30
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25
已完成
不适用
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790MJPRN-UMIN000015568Okayama University Hospital12
进行中（未招募）
1 期
Evaluation of efficacy of gefitinib drug in patients with non-small cell tumors with EGFR and TP53 gene mutatioon-small cell lung cancer (NSCLC) at the stageadvanced / metastatic with receptor sensitizing mutation for growth factorepidermal (EGFR)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002626-20-ITAZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA54